Welcome to our dedicated page for Coherus Bioscien news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Bioscien stock.
Coherus BioSciences (NASDAQ: CHRS) is a commercial-stage biopharmaceutical company advancing innovative oncology therapies, including immunotherapies and biosimilars. This page provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping cancer care.
Discover comprehensive coverage of CHRS news, including FDA approvals, partnership announcements, and pipeline advancements. Our curated updates ensure you stay informed about the company activities that matter most—from late-stage clinical trials to commercialization strategies for oncology biosimilars.
Key focus areas include updates on immuno-oncology candidates targeting tumor microenvironments, progress in expanding global biosimilar access, and analyses of strategic collaborations. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for direct access to Coherus BioSciences' latest press releases and news. Check back regularly for authoritative insights into one of oncology’s most dynamic innovators.
Coherus BioSciences (NASDAQ: CHRS) presented promising Phase 1 clinical trial data for CHS-114, their selective anti-CCR8 antibody, in combination with toripalimab for head and neck squamous cell carcinoma (HNSCC) treatment at AACR 2025.
Key findings include:
- Confirmed partial response in a heavily pretreated PD-1 refractory patient
- >50% depletion in CCR8+ Treg cells
- Significant increase in CD8+ T cells
- Manageable safety profile consistent with advanced disease
The study evaluated CHS-114 as monotherapy and in combination with toripalimab in 21 patients with advanced solid tumors. A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing, with results expected in first half of 2026.
Coherus BioSciences (NASDAQ: CHRS) has completed the divestiture of its UDENYCA® franchise to Intas Pharmaceuticals in a deal valued at up to $558.4 million. The transaction includes an upfront payment of $483.4 million (with $118.4 million for UDENYCA inventory) and potential milestone payments of up to $75 million.
The deal provides Coherus with a $250 million post-close cash balance, extending runway into 2027. The company will now focus exclusively on innovative oncology programs including:
- LOQTORZI® - a revenue-generating PD-1 inhibitor
- Casdozokitug - a first-in-class IL-27 antagonist
- CHS-114 - a selective CCR8 antibody
The transaction closed on April 11, 2025, with Accord BioPharma, Intas' U.S. specialty division, assuming full responsibility for the UDENYCA franchise in the U.S.
Coherus BioSciences (NASDAQ: CHRS) has announced plans to repurchase approximately $170 million of its 1.500% Convertible Senior Subordinated Notes due 2026 through privately negotiated transactions. The repurchase will be executed at 100% of principal amount plus accrued interest.
The repurchase is contingent on the closing of the previously announced UDENYCA franchise divestiture to Intas Pharmaceuticals Following this initial repurchase, about $60 million in convertible notes will remain outstanding, which Coherus intends to repurchase after the transaction closes.
Additionally, holders representing a majority of the outstanding notes have agreed to provide consent for amendments to the indenture, allowing the UDENYCA divestiture to proceed.
Coherus BioSciences (NASDAQ: CHRS) has announced the upcoming presentation of interim data from its ongoing Phase 1 clinical trial of CHS-114, a selective, cytolytic anti-CCR8 antibody, at the 2025 AACR Annual Meeting. The study evaluates CHS-114 both as a monotherapy and in combination with toripalimab for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
The presentation, led by Dr. Francis Worden from the University of Michigan, will be featured as a poster (Abstract #CT038) in the Phase 0 and Phase 1 Clinical Trials section. The session is scheduled for Monday, April 28, 2025, from 9:00 a.m. to 12:00 p.m. CDT at McCormick Place Convention Center in Chicago.
Coherus BioSciences (CHRS) reported its Q4 and full year 2024 results, with annual net revenue increasing 4% to $267.0 million. The company's transformation highlights include strong performance of key products: UDENYCA® net revenue grew 62% year-over-year, while LOQTORZI® sales increased 29% quarter-over-quarter.
A significant development is the planned UDENYCA divestiture for up to $558.4 million, expected to close in late Q1 or early Q2 2025. Post-divestiture, Coherus projects approximately $250 million in cash, providing a runway exceeding two years. The company plans to reduce headcount by 30% to about 155 employees.
The company's focus shifts to oncology, with LOQTORZI receiving preferred status in NCCN guidelines for nasopharyngeal carcinoma treatment. Multiple clinical data readouts are expected across their oncology pipeline in 2025/2026, including developments in casdozokitug and CHS-114 programs.
Coherus BioSciences (NASDAQ: CHRS) has scheduled its fourth quarter and full year 2024 financial results announcement for March 10, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. ET on the same day, where management will discuss financial results and provide a business update.
Investors and interested parties can pre-register for the conference call through a provided link to receive dial-in information and a personal PIN. A live webcast will be available, and both the press release containing the financial results and an archived version of the webcast will be accessible through the company's investor relations website.
Coherus BioSciences (NASDAQ: CHRS) has announced its senior management's upcoming participation in the 45th Annual TD Cowen Health Care Conference. The company will engage in a fireside chat presentation scheduled for Tuesday, March 4, 2025, at 11:50 a.m. Eastern time.
Investors and interested parties can access a live audio webcast of the presentation through the 'Events and Presentations' section of Coherus' investor website. The presentation recording will remain available for approximately 90 days following the event on the company's investor portal at https://investors.coherus.com/events-presentations.
Coherus BioSciences (NASDAQ: CHRS) announced final Phase 2 clinical trial data for casdozokitug (casdozo) in combination with atezolizumab and bevacizumab for treating hepatocellular carcinoma (HCC). The trial showed improved results with an overall response rate of 38% (up from 27%) and complete response rate of 17.2% (up from 10.3%).
The study involved 30 treatment-naïve patients with unresectable locally advanced or metastatic HCC. Key findings include median progression-free survival of 8.1 months and disease control rate of 58.6% under RECIST v1.1 criteria. The treatment demonstrated efficacy across both viral and non-viral disease types with no new safety concerns.
Based on these promising results, Coherus has initiated a new randomized Phase 2 study combining casdozo with bevacizumab and toripalimab, expected to enroll up to 72 patients.
Coherus BioSciences (NASDAQ: CHRS) has announced that its senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time.
The presentation, which will include a Q&A session, will be accessible via Webcast through a link on the Investor Events Calendar section of the Coherus website. The webcast will be available for replay until February 10, 2025.
For further information, investors can contact Jodi Sievers, VP of Investor Relations & Corporate Communications, at IR@coherus.com.
Coherus BioSciences (NASDAQ: CHRS) will present final Phase 2 clinical trial data for casdozokitug (casdozo) at ASCO-GI 2025. The study evaluated casdozo, an IL-27-antagonistic antibody, in combination with atezolizumab and bevacizumab for treating metastatic hepatocellular carcinoma (HCC).
The company has initiated a new randomized Phase 2 study (NCT06679985) testing casdozo with bevacizumab and toripalimab in first-line HCC patients. This study will enroll up to 72 patients to evaluate safety, efficacy, and Project Optimus dosing of the triplet combination.
Previous Phase 3 HEPATORCH study results showed toripalimab with bevacizumab achieved 25.3% objective response rate versus 6.1% for sorafenib, with median overall survival of 20 months versus 14.5 months.
FAQ
What is the current stock price of Coherus Bioscien (CHRS)?
What is the market cap of Coherus Bioscien (CHRS)?
